Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer
Open Access
- 27 December 2025
- journal article
- Published by Elsevier in Journal of the National Cancer Center
- Vol. 6 (1) , 88-97
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitorsActa Pharmaceutica Sinica B, 2025
- Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignanciesCancer Cell, 2024
- Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancerThe Journal of Pathology, 2024
- Characterization of HOXB13 expression patterns in localized and metastatic castration‐resistant prostate cancerThe Journal of Pathology, 2023
- FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancerCancer Cell, 2022
- AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2021
- Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin DysregulationCancer Cell, 2020
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerCancer Cell, 2016
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial CellsCancer Cell, 2016
- Stabilization of N-Myc Is a Critical Function of Aurora A in Human NeuroblastomaCancer Cell, 2009